Envista Holdings Corp Stock Price, News & Analysis

Envista Holdings Corporation (NYSE: NVST) has successfully completed the sale of its KaVo Treatment Unit & Instrument business, receiving $317.3 million in cash upon closing. The total gross proceeds from the divestiture are projected to reach $383 million, which includes earnouts to be received by mid-2022. This strategic move allows Envista to allocate funds towards acquisitions and internal investments, enhancing its offerings to dental professionals. The Imaging business under the KaVo brand will remain with Envista.

Envista Holdings Corporation (NYSE: NVST) announced FDA clearance for its Nobel Biocare N1™ implant system, enhancing patient-centric solutions. This system integrates innovative features like the OsseoShaper™, which optimizes site preparation, improves patient comfort, and reduces noise compared to traditional methods. The N1™ also includes advanced surface treatments and is compatible with digital workflows via DTX Studio™. CEO Amir Aghdaei highlighted the growing demand for high-quality solutions in implantology. This development positions Envista to set new standards in dental implant treatment.

Envista Holdings Corporation (NYSE: NVST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2022, at 12:00 PM PST. The presentation will be virtual, and investors can access recordings on Envista's Investor Relations website under Events and Presentations. Envista is a prominent global dental products company, offering a comprehensive range of solutions to cater to dental professionals’ needs, which includes brands like Nobel Biocare and KaVo.

Envista Holdings Corporation (NYSE: NVST) announced a definitive agreement to acquire Carestream Dental's Intra-Oral Scanner business for $600 million, expected to close in Q2 2022. This acquisition aligns with Envista's strategy to capture high-growth segments in the dental market, featuring anticipated annual sales of $60 million in 2021. The acquisition is set to enhance Envista's offerings in digital dental workflows, leveraging world-class intra-oral scanners critical for procedures like implants and prosthetics. The transaction is subject to regulatory approvals.

Envista Holdings Corporation (NYSE: NVST) announced its participation in several upcoming investor conferences. Key events include the Stifel MedTech Madness on December 15, 2021, the Goldman Sachs Healthcare CEOs Unscripted Conference on January 6, 2022, and the J.P. Morgan Healthcare Conference on January 10, 2022. Investors can access recordings of these presentations on Envista's Investor Relations website. As a leading global dental products company, Envista operates over 30 trusted dental brands and aims to enhance patient care through innovative solutions.

Envista Holdings Corporation (NYSE: NVST) reported a strong third quarter 2021, achieving sales of $607.3 million, an 11% increase, with core sales growing 10.2% year-over-year. Net income was $80.2 million or $0.45 per diluted share. The company raised its full-year guidance for sales to $2.475 - $2.500 billion and adjusted EBITDA to $480 - $495 million. CEO Amir Aghdaei expressed optimism for the dental industry, noting a focus on differentiated products and strong digital solutions. Adjusted EBITDA margin stood at 19.6%, highlighting profitability.

Envista Holdings Corporation (NYSE: NVST) will report its third quarter 2021 financial results on November 3, 2021. A conference call to discuss these results is scheduled for 2:00 PM PT, lasting approximately one hour. Investors can access the call by dialing 877-876-9173 for U.S. participants or +1 785-424-1667 internationally. The call will also be available via webcast on Envista's website, with a replay accessible after the presentation. Detailed materials will be posted prior to the call.

Envista Holdings Corporation (NYSE: NVST) announced the sale of its KaVo Treatment Unit and Instrument business to Planmeca for up to $455 million, including a $30 million earn-out. This divested segment generated $357 million and $317 million in revenue in fiscal years 2019 and 2020, respectively. The deal is expected to close by the end of 2021 and will be reported as a discontinued operation starting Q3 2021. The transaction is not dependent on financing or a shareholder vote.

Envista Holdings Corporation (NYSE: NVST) announced its participation in the Baird Global Healthcare Virtual Conference on September 14, 2021, at 2:35 PM ET. Investors can access the presentation via Envista's Investor Relations website under the Events and Presentations section. Envista is a leading global provider of dental products, boasting over 30 trusted brands, including KaVo Kerr and Nobel Biocare. The company focuses on innovation and customer support to address dental professionals' needs.